Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA topoisomerase type II (Topo II) is a dimeric enzyme that manages DNA topology by creating transient double-stranded DNA breaks, passing another DNA duplex (T-segment) through the break in the gate-segment (G-segment), and religating the break in an ATP-dependent manner. It features an N-terminal GHKL ATPase domain, a Toprim domain for Mg2+-dependent cleavage, a central DNA-binding core forming a heart-shaped structure with N-gate, DNA-gate, and C-gate interfaces, and a variable C-terminal domain. The enzyme undergoes conformational changes, including ATPase domain dimerization upon ATP binding, domain swapping, and a lysine-rich loop interaction with bent G-segment DNA to couple DNA binding to ATP hydrolysis, ensuring unidirectional strand passage for processes like replication, transcription, chromosome segregation, and supercoil relaxation.[1][2][3][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA topoisomerase type II (Topo II).